Aqtual is at the forefront of advancing precision medicine, particularly in the management of chronic diseases and oncology. The company leverages proprietary biochemistry and advanced data science to create a comprehensive catalog of disease-specific clinical features. Aqtual's innovative approach includes the development of highly accurate blood tests aimed at disease detection, monitoring, and patient stratification across various chronic inflammatory conditions and cancer. Their mission emphasizes bridging the gap between groundbreaking research and practical healthcare solutions, ultimately improving patient outcomes in some of the costliest disease areas.

Aqtual has made significant strides in the field of epigenetics and gene regulation by discovering a method to analyze cell-free DNA from a single blood draw. This breakthrough allows for the capture of circulating chromatin and DNA fragments that are typically difficult to access through conventional laboratory techniques. The company is focused on creating a validated catalog of clinically actionable signatures that can inform drug development and therapeutic strategies across multiple therapeutic areas, including inflammatory conditions, oncology, immunology, cardiovascular diseases, metabolic diseases, and neurological conditions. Their initial focus on rheumatoid arthritis aims to develop a blood test that can guide therapy management, with ongoing clinical studies to validate their findings in real-world settings.

United States

Aqtual, Inc. is a precision medicine company using its novel cell-free DNA platform to develop products for chronic diseases and oncology. Our mission is to revolutionize the treatment and management of these conditions by bridging the translational gap between groundbreaking research and practical healthcare solutions.


Aqtual

Company Details